All In Biotech

Drug Trial Radar · NCT06793670

Landiolol in Mitral Valve Surgery

The Use of Landiolol in Mitral Valve sUrgery: a raNdomized, Controlled, Double-blind triAl (LUNA)

Last checked: Nov 21, 2026Latest source record: Dec 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 1,500 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,500

Planned (sponsor's estimate)

Start

Jan 28, 2025

Primary completion

Jun 2027

Study completion Dec 2027

Sponsor

Lead sponsor
Università Vita-Salute San RaffaeleAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 27, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Chronic mitral regurgitation is the most common valvular abnormality worldwide, it occurs in 10% of the general population and its prevalence increases with age. When left untreated, it can lead to left ventricular dysfunction and cause disabling symptoms (e.g., fatigue and dyspnea), life-threatening complications (e.g., ventricular dilation, congestive heart failure) and death. Surgical correction of chronic mitral regurgitation before irreversible changes happen can be curative. Open surgical valve repair or replacement are accomplished through cardiopulmonary bypass and cardioplegic arrest. Myocardial protection is essential to guarantee an uneventful perioperative course since a not-well protected heart may lead to postoperative low-cardiac output syndrome. This occurs in 30% of high-risk patients who undergo elective cardiac surgery and is associated with 20% mortality. Cardioplegia preserves the heart during ischemic arrest by reducing its metabolic demand. The most effective cardioplegia for protection in adult cardiac surgery remains unknown and improving the protection of the heart during the ischemic arrest may potentially improve patients' postoperative outcomes. Pharmacological adjuvants to the cardioplegic solutions have been tested to mitigate the ischaemic-reperfusion injury following cardiac surgery. Ultra-short acting beta-blockers (e.g., esmolol, landiolol) decrease intraoperative myocardial metabolic demand and suppress the sympathetic response to surgical stimuli while exhibiting limited adverse effects. Few studies with limited sample size investigated the role of ultra-short acting beta-blockers in reducing perioperative ischaemia and arrhythmia after cardiac surgery. When ultra-short acting beta-blockers were administered before aortic cross-clamping and as cardioplegia adjuvant we observed a trend towards a reduction in postoperative low-cardiac output syndrome (13/98 vs 6/102; p=0.08) and in the rate of hospital re-admission at one year (26/95 v 16/96, p=0.08) with an increase in the number of patients with ejection fraction \>60% at hospital discharge (4/95 vs 11/92, p=0.06) (Zangrillo 2021). However, despite a growing body of literature exploring the role of ultra-short acting beta-blockers in enhancing myocardial protection during on-pump cardiac surgery, further high-quality evidence is needed before this practice can be established as standard routine care. Hence, we designed a randomized, placebo-controlled trial involving 1500 patients undergoing open mitral valve surgery to assess the effect of administering landiolol as cardioplegia adjuvant to reduce the occurrence of postoperative low-cardiac output syndrome. Successful results would have a significant impact on short and long-term complications.

Conditions

  • Cardiac Failure
  • Low Cardiac Output Syndrome

Interventions

  • LandiololDrug

    Intravenous infusion of landiolol

  • PlaceboDrug

    Intravenous infusion of saline solution of NaCl 0.9%

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Reduction of the occurrence of postoperative low-cardiac output syndrome (LCOS)Time frame: Until ICU discharge, an average of 4 days

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • AOU di Alessandria

    Alessandria, Italy · Recruiting

  • Azienda Ospedaliero Universitaria Policlinico "G.Rodolico - San Marco"

    Catania, Italy · Recruiting

  • AOU Careggi

    Florence, Italy · Recruiting

  • Azienda Ospedaliero Universitaria Ospedali Riuniti di Foggia

    Foggia, Italy · Recruiting

  • IRCCS San Martino di Genova

    Genova, Italy · Recruiting

  • Ospedale San Raffaele

    Milan, Italy · Recruiting

  • ASST Grande Ospedale Metropolitano Niguarda

    Milan, Italy · Recruiting

  • AOU Policlinico Paolo Giaccone

    Palermo, Italy · Recruiting

  • Azienda Ospedaliero Universitaria Pisana

    Pisa, Italy · Recruiting

  • AOR San Carlo

    Potenza, Italy · Recruiting

  • Maria Cecilia Hospital S.p.A.

    Ravenna, Italy · Recruiting

  • Ospedale Cesare Arrigo

    Alessandria, Piedmont, Italy · Recruiting

  • A. O. Ordine Mauriziano di Torino

    Torino, TO, Italy · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.